NASDAQ: GLPGGalapagos Nv Stock
$34.30-0.14 (-0.41%)
Updated Sep 27, 2023
GLPG Price
$34.30
Fair Value Price
$42.04
Market Cap
$2.26B
52 Week Low
$34.25
52 Week High
$48.07
P/E
N/A
P/B
0.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.81
Operating Cash Flow
N/A
Beta
0.8
Next Earnings
Nov 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
GLPG Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GLPG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLPG ($34.30) is undervalued by 18.41% relative to our estimate of its Fair Value price of $42.04 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GLPG ($34.30) is not significantly undervalued (18.41%) relative to our estimate of its Fair Value price of $42.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more GLPG due diligence checks available for Premium users.
Be the first to know about important GLPG news, forecast changes, insider trades & much more!
GLPG News
Valuation
GLPG fair value
Fair Value of GLPG stock based on Discounted Cash Flow (DCF)
Price
$34.30
Fair Value
$42.04
Undervalued by
18.41%
GLPG ($34.30) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLPG ($34.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLPG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
13.5x
Market
13.45x
GLPG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
5.12x
GLPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLPG's financial health
Profit margin
Revenue
$194.4M
Net Income
$25.2M
Profit Margin
13%
Assets to liabilities
Assets
$5.0B
Liabilities
$2.2B
Debt to equity
0.81
GLPG's short-term assets ($4.57B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLPG's short-term assets ($4.57B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLPG's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GLPG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$105.5M
Investing
-$313.8M
Financing
-$206.5k
GLPG vs Biotech Stocks
Galapagos Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.